---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-007965"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:22:06.595298+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies announces validation study with Brooke Army Medical Center for CyPath Lung test

## Summary
- Study with BAMC to validate CyPath Lung on sputum obtained by tracheal/bronchial suctioning for early lung cancer detection.
- Enrolling 30-50 patients; results expected by mid-2026.
- Potential to expand sample collection options; currently patients collect sputum at home.
- U.S. bronchoscopy procedures ~500,000 annually; market valued at $700-920M.

## SEC filing metadata
- accession: 0001493152-26-007965
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226007965/0001493152-26-007965-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226007965/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-007965
- JSON: https://secwatch.observer/filing/0001493152-26-007965.json
- Plain text: https://secwatch.observer/filing/0001493152-26-007965.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.